Poly(amine-co-ester) nanoparticles and methods of use thereof
Polymers including poly(amine-co-ester), poly(amine-co-amide), or a combination thereof, and nanoparticles, particularly solid core nanoparticles, formed therefrom are provided. Solid core nanoparticles fabricated from hydrophobic polymers often require the presence of cationic complexing agents to stabilize negatively charged active agents such as siRNA. However, complexing agents are optional in the disclosed formulations because the nanoparticles contain cationic amines to stabilize negatively charged nucleic acids and hydrophobic domains to condense the nucleic acid into the core of the formed nanoparticles, thus improving encapsulation efficiency. This increase in nucleic acid loading allows the disclosed solid core nanoparticles to deliver more nucleic acid per cell without increasing total polymer delivered, further reducing cytotoxicity. Pharmaceutical compositions including an effective amount of the nanoparticles are also provided, and be used, for example, for in vitro and in vivo delivery of nucleic acids.
1. A solid polymeric nanoparticle comprising a polymer having the general formula:
((A) x -(B) y -(C) q -(D) w -(E) f ) h ,
wherein A, B, C, D, and E are independently a lactone unit, a polyfunctional molecule comprising one or more cations, one or more positively ionizable atoms, or combinations thereof, a diacid or diester, or polyalkylene oxide;
wherein at least one lactone unit is
wherein at least one polyfunctional molecule is
wherein at least one diacid or diester is
wherein the polymer comprises the structure:
wherein w and f are independently integers from 0-1000;
x, y, and q are independently integers from 1-1000;
wherein h is an integer from 1 to 1000;
wherein n is an integer from 1-30;
wherein m, o, and p are independently an integer from 1-20;
Z and Z′ are independently O or NR′, wherein R and R′ are independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted aryl; and
wherein the percent composition of the lactone unit is between about 30% and about 100%, calculated as the mole percentage of the total number of moles of the lactone unit divided by the sum of the total number of moles of the lactone unit and either the total number of moles of the diacid or the total number of moles of the diester, or
wherein the molar ratio of the total number of moles of the lactone unit divided by the sum of the total number of moles of the lactone unit and either the total number of moles of the diacid or the total number of moles of the diester is between about 0.3 and about 1.
2. The solid polymeric nanoparticle of claim 1 , wherein the number of carbon atoms in the lactone unit of the polymer is between about 10 and about 24.
3. The solid polymeric nanoparticle of claim 1 prepared by double emulsion.
4. The solid polymeric nanoparticle of claim 1 , further comprising an active agent encapsulated, entrapped, embedded, or dispersed therein, or complexed thereto.
5. The solid polymeric nanoparticle of claim 4 , wherein the active agent is a polynucleotide.
6. The solid polymeric nanoparticle of claim 5 , wherein the polynucleotide is composed of DNA, RNA, synthetic nucleotides, or a combination thereof.
7. The solid polymeric nanoparticle of claim 6 , wherein the polynucleotide is composed of RNA.
8. The solid polymeric nanoparticle of claim 6 , wherein the polynucleotide is an siRNA or an siRNA mimic.
9. A method of delivering an active agent to cells comprising contacting the cells with an effective amount of the solid polymeric nanoparticle of claim 4 and pharmaceutically acceptable carrier.
10. The method of claim 9 wherein the contacting occurs in vitro.
11. The method of claim 9 wherein the contacting occurs in vivo.
12. The method of claim 9 , wherein the cells express a target gene, the active agent is an inhibitory nucleic acid that reduces expression of the target gene, or transcript, or protein thereof, and the cells are contacted with an effective amount of a pharmaceutical composition to reduce expression of the target gene, or transcript, or protein thereof in the cells.
13. The method of claim 12 , wherein the inhibitory nucleic acid is siRNA.
14. The method of claim 12 , wherein the contacting occurs in vivo.
15. The method of claim 12 , wherein the solid polymeric nanoparticle is administered to a subject in need thereof in an effective amount for the inhibitory nucleic acid to reduce one or more disease or disorder symptoms in the subject.
16. The method of claim 15 , wherein reduced expression of the target gene in the subject is sustained for at least 2 weeks.